Skip to content

Expression of IL-39 in serum of patients with gout and its clinical significance

Expression of IL-39 in serum of patients with gout and its clinical significance

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600126391
Enrollment
Unknown
Registered
2026-06-08
Start date
2026-06-08
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gout

Interventions

Remission gout group:None
Acute gout group:None
Healthy control group:None

Sponsors

Ningbo First Hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Acute Gout Group: (1) Male, aged 18–80 years; (2) Meet the 2015 ACR/EULAR gout classification criteria with a score =8 points; (3) In the acute flare phase of gout, defined as sudden redness, swelling, pain, fever, and tenderness in the affected joint or bursa; (4) Blood sample collected within 72 hours of symptom onset, and no use of non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, or glucocorticoids before blood collection. 2.Remission Gout Group: (1) Male, aged 18–80 years; (2) Previously definite diagnosis of gout; (3) At least 3 months since the last gout flare; (4) No acute inflammatory manifestations (redness, swelling, pain, fever, tenderness) in the affected joint or bursa in the past 3 months; (5) No active infection, fever, or other acute inflammation at the time of blood collection. 3.Healthy Control Group: Male, aged 18–80 years; healthy individuals from the same period’s health examination center, with no history of gout, autoimmune diseases, tumors, or chronic inflammatory diseases; normal liver and kidney function and normal inflammatory markers.

Exclusion criteria

Exclusion criteria: 1.Complicated with other autoimmune diseases such as rheumatoid arthritis, psoriatic arthritis, or systemic lupus erythematosus. 2.Complicated with acute infection, malignant tumor, severe cardiac, hepatic, or renal insufficiency, or immunodeficiency disease. 3.Use of immunosuppressants, or biologics within the past 3 months. 4.Incomplete medical records, unable to determine disease stage, or missing key clinical indicators.

Design outcomes

Primary

MeasureTime frame
Serum IL-39 concentration;

Secondary

MeasureTime frame
C-reactive protein (CRP);White blood cell count (WBC);Liver function tests (ALT?AST?GGT?TBIL?DBIL?IBIL);Lipid profile (TG, TC, HDL-C, LDL-C);Absolute Neutrophil Count (ANC);Serum uric acid (UA);Renal function tests (Creatinine, Urea);Serum Amyloid A;Erythrocyte sedimentation rate (ESR);

Countries

China

Contacts

Public ContactTingqi Zhao

Ningbo First Hospital

ztq007@126.com+86 574 8703 5649

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026